Crowdonomics
WatchlistPortfolio
All companies
32 Biosciences logo

32 Biosciences

Operating

32 Biociences, Inc.

Biotech · Biotech · North Chicago, IL · Founded 2023

Visit website

Diversified life science company focused on gut microbiome medicine

Valuation cap ⓘ
$31.2M
As of Feb 2025 · from Reg CF Offering (2024) · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$4,018,598
Crowd $509K · Private $3.5M · 5 rounds since 2022
Latest share price
$0.8088
Section 4(a)(2) · Common Stock · Jan 2022 offering price

Financials

FY2022–FY2025 · from SEC filings · hover any figure for its source
$0
2022
$0
$3K
2023
$54K
−$1.7M
2024
$0
−$3.1M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022 reviewed*
FY2023 reviewed*
FY2024
FY2025
Income statement
Revenue
$0
$0
$53,691
$0
Cost of goods sold
$0
$0
$0
$0
Gross margin
—
—
100%
—
Net income
$0
$3,111
-$1,742,797
-$3,091,429
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$0
$3,277
$1,183,699
$1,857,311
Accounts receivable
$0
$0
$0
$0
Total assets
$0
$3,227
$1,478,698
$2,091,486
Short-term debt
$0
$116
$14,917
$358,681
Long-term debt
$0
$0
$3,177,281
$5,378,215
Total liabilities
$0
$116
$3,192,198
$5,736,896
Other
Headcount
—
4
8
7

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Valuation caps on SAFE / convertible note rounds
$31.2M
Valuation cap
Reg CF · SAFE · Jun 2024

Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.

Fundraising history

Section 4(a)(2) · SAFE · Mar 2025Closed
Raised $1.1M
Reg CF · SAFE · Jun 2024Closedvia Republic
Raised $508.6K / $1.2MInvestors 236Valuation cap $31.2M
Rule 506(b) · Equity · May 2024Closed
Raised $160KInvestors 3
Rule 506(b) · SAFE · Apr 2023Closed
Raised $2M

Team

6 people
Peter Farmakis
Chief Executive Officer
Brian Yoor
Director
Eugene Chang
Director
Jaime Contreras
Director
John Alverdy
Director
Joseph Pierre
Director

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 2 of 2 annual reports (FY2024–FY2025)

236 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-TRApr 24, 20260002020332-26-000004
    EDGAR
  • Form C-ARApr 24, 20260002020332-26-000003
    EDGAR
  • Form C-ARApr 30, 20250002020332-25-000002
    EDGAR
  • Form C-UJan 2, 20250002020332-25-000001
    EDGAR
  • Form C/AOct 9, 20240002020332-24-000005
    EDGAR
  • Form CJun 24, 20240002020332-24-000002
    EDGAR
  • Form DMay 31, 20240002020332-24-000001
    EDGAR
Source: ManualCIK 0002020332ILShare price $0.8088

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.